Incyte Genomics and Genicon Sciences Team up to Measure Smallest Proteins Detectable Palo Alto, CA and San Diego, CA February 15, 2001 - Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomic information company, and Genicon Sciences Corporation, a privately held San Diego-based company, today announced plans to jointly develop resources for the detection of infinitesimal levels of proteins present in biological samples. Genicon Sciences' RLS (Resonance Light Scattering) Technology™ will be employed in Incyte's antibody array products that are scheduled to be introduced later this year. Under the terms of the agreement, Incyte will receive certain rights to co-develop and commercialize Genicon's proprietary RLS Technology with Incyte array products. Financial terms were not disclosed. Incyte markets LifeArray chips for third party microarray operations and is developing antibody array products. The parties believe that the RLS detection system has the potential to provide more precise measurements and capture a significant share of the $600 million market for radioactive, fluorescent, chemiluminescent, and other labeling systems, including ELISA (Enzyme-Linked Immunosorbent Assay), currently in use for similar genomic products. "The combination of RLS Technology with Incyte's array products and reagents will empower researchers with the most sensitive and robust set of genomic and proteomic tools available," said Roy A. Whitfield, Chief Executive Officer of Incyte. "Most processes in biology are controlled by proteins. We expect that Incyte's antibody arrays, treated with the RLS detection system, will provide faster and more cost-effective tools for measuring hundreds of proteins from thousands of biological samples. These new products should reduce the time scientists will need to identify a gene that might be implicated in a disease or a gene that might affect the efficacy or safety of a drug," Whitfield said. "The incorporation of RLS Technology into Incyte's proprietary commercial offerings will enhance what is already the most sensitive and reproducible microarray information currently available," said Patrick J. Mallon, Genicon's President and Chief Executive Officer. "This is a key alliance that underscores our 'open access' business model of leveraging Genicon's proprietary RLS Technology while enabling other commercial and proprietary technologies for use in the genomics and proteomics market." Incyte Genomics, Inc. is the leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, genomic data management software, microarray-based gene expression services, related reagents and services. These products, programs, and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development, including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's web site at www.incyte.com. Genicon Sciences Corporation, headquartered in San Diego, California, is a privately held company focused on the detection, measurement and analysis of biological interactions, which serves as the fundamental basis for a broad array of in vitro test systems within the pharmaceutical, biotechnology, genomics and diagnostics industries. Genicon Sciences has developed the RLS Technology™, an ultra-sensitive signal generation and detection platform technology for the simple and efficient detection, measurement and analysis of biological interactions. The Company provides "open access" to its technology products. For more information, please visit our web site at www.geniconsciences.com. Except for the historical information contained herein, the matters set forth in this press release, including statements as to the expected timing of the launch of Incyte's antibody array products, the potential for the RLS detection system to provide more precise measurements and capture market share, the efficacy, speed and cost-effectiveness of Incyte's antibody arrays, and the impact of the use of those arrays on users' ability to identify genes, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties related to timely product development and manufacture, the ability of the parties to work together to create arrays using RLS Technology, the impact of competition and technological advances, and other risks detailed from time to time in Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2000. Incyte disclaims any intent or obligation to update these forward-looking statements.